Compare GraniteShares 2x Long NVDA Daily ETF (NVDL) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GraniteShares 2x Long NVDA Daily ETF vs BIO-TECHNE Corp — how do they compare? GraniteShares 2x Long NVDA Daily ETF trades at $34.5, while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: BIO-TECHNE Corp pays a 0.44% dividend while GraniteShares 2x Long NVDA Daily ETF pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, GraniteShares 2x Long NVDA Daily ETF nearer its low. Which is the better fit depends on your goals.
| NVDL | TECH | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $43.02 | $72.29 |
52-Week Low | $21.76 | $43.31 |
Market Cap | — | $11.24B |
Enterprise Value | — | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVDL, a leveraged ETF tracking 2x the daily performance of NVIDIA, trades at $36.43, up 4.56% in 24 hours. Technical indicators show a bullish trend with strong moving average support, though the 6-day RSI at 98.95 signals overbought conditions. Recent stock splits (1:3 on June 25-26, 2026) adjust share structure, while news highlights mixed performance relative to NVIDIA's AI-driven gains.
The outlook hinges on NVIDIA's AI dominance, with potential for amplified returns via leverage, but daily reset mechanics pose volatility risks. Key risks include tracking errors and market corrections, warranting caution for long-term holders amid bullish technicals.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GraniteShares 2x Long NVDA Daily ETF
NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.
Read more on NVDL →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
